Physician profile
Alfonso Chen
NPI 1649222514
$903.64
in general payments reported to CMS, 2019-2025
11 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $19.34 · 2021: $58.50 · 2022: $123 · 2023: $241 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.08 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.37 | 2021-2023 | |
| Abbvie INC. | $158.72 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $137.91 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $105.45 | 2019 | |
| Lundbeck LLC | $39.91 | 2019-2023 | Rexulti |
| Allergan, INC. | $33.14 | 2019-2020 | |
| Alkermes, INC. | $25.03 | 2023 | Lybalvi |
| Validus Pharmaceuticals LLC | $23.97 | 2020-2025 | Equetro, Raldesy |
| Teva Pharmaceuticals USA, INC. | $22.03 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfonso Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.